Modalis Therapeutics Corporation (TYO:4883)
Japan · Delayed Price · Currency is JPY 33.00
0.00 (0.00%)
Aug 27, 2026, 3:30 PM JST
Modalis Therapeutics Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | - | - | - | 40 | 1 | |
Revenue Growth | - | - | - | - | 3900.00% | -99.71% |
Gross Profit | - | - | - | - | 40 | 1 |
Selling, General & Admin | 171 | 207 | 220 | 248 | 213 | 196 |
Research & Development | 1,973 | 1,979 | 1,092 | 2,102 | 1,861 | 1,009 |
Other Operating Expenses | 25 | 25 | 25 | 20 | 29 | 35 |
Operating Expenses | 2,133 | 2,211 | 1,337 | 2,370 | 2,103 | 1,240 |
Operating Income | -2,133 | -2,211 | -1,337 | -2,370 | -2,063 | -1,239 |
Interest Expense | -17 | -9 | -8 | -15 | -4 | -1 |
Interest & Investment Income | 4 | 3 | - | - | - | - |
Currency Exchange Gain (Loss) | 51 | 10 | 64 | 39 | 76 | 12 |
Other Non Operating Income (Expenses) | 47 | 58 | -23 | -6 | -4 | 1 |
EBT Excluding Unusual Items | -2,048 | -2,149 | -1,304 | -2,352 | -1,995 | -1,227 |
Gain (Loss) on Sale of Assets | 17 | - | - | - | - | -2 |
Asset Writedown | -3 | -2 | - | -38 | -996 | - |
Other Unusual Items | - | - | -13 | - | 285 | 485 |
Pretax Income | -2,034 | -2,151 | -1,317 | -2,390 | -2,706 | -744 |
Income Tax Expense | 7 | 1 | - | 1 | -4 | -6 |
Net Income | -2,041 | -2,152 | -1,317 | -2,391 | -2,702 | -738 |
Net Income to Common | -2,041 | -2,152 | -1,317 | -2,391 | -2,702 | -738 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 86 | 77 | 46 | 31 | 29 | 29 |
Shares Outstanding (Diluted) | 86 | 77 | 46 | 31 | 29 | 29 |
Shares Change | 32.19% | 67.52% | 48.96% | 6.39% | 1.23% | 9.12% |
EPS (Basic) | -23.61 | -27.85 | -28.55 | -77.21 | -92.83 | -25.67 |
EPS (Diluted) | -23.61 | -27.85 | -28.55 | -77.21 | -92.83 | -25.67 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -1,904 | -2,120 | -1,432 | -2,293 | -2,092 | -854 |
Free Cash Flow Per Share | -22.03 | -27.44 | -31.05 | -74.05 | -71.87 | -29.70 |
Gross Margin | - | - | - | - | 100.00% | 100.00% |
Operating Margin | - | - | - | - | -5157.50% | -123900.00% |
Profit Margin | - | - | - | - | -6755.00% | -73800.00% |
Free Cash Flow Margin | - | - | - | - | -5230.00% | -85400.00% |
EBITDA | - | - | -1,336 | -2,369 | -1,940 | -1,162 |
D&A For EBITDA | - | - | 0.73 | 0.73 | 123 | 77 |
EBIT | -2,133 | -2,211 | -1,337 | -2,370 | -2,063 | -1,239 |